Successful osimertinib rechallenge after severe thrombocytopenia caused by osimertinib combined with sitagliptin: a case report

被引:1
作者
Tan, Xinyuan [1 ,4 ]
Chen, She [2 ]
He, Liu [3 ]
Huang, Minling [1 ]
Zhang, Xiaoshan [1 ]
机构
[1] Guangdong Prov Hosp Chinese Med, Dept Pulm & Crit Care Med, Guangzhou, Peoples R China
[2] Guangzhou Univ Chinese Med, Dept Pharm, Affiliated Hosp 2, Guangzhou, Peoples R China
[3] Guangdong Prov Acad Chinese Med Sci, Guangzhou, Peoples R China
[4] Guangdong Prov Acad Chinese Med Sci, Guangdong Prov Hosp Chinese Med, Dept Pulm & Crit Care Med, Guangzhou, Peoples R China
关键词
adverse events; non-small cell lung cancer; osimertinib; platelet; sitagliptin; thrombocytopenia; OPEN-LABEL; PHASE-II; LUNG; NSCLC;
D O I
10.1097/CAD.0000000000001443
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Osimertinib is recommended as the first-line treatment of advanced non-small cell lung cancer (NSCLC) in adults. The most commonly reported adverse events for osimertinib are skin effects, diarrhea, nausea, decreased appetite, fatigue, paronychia, and stomatitis. Severe thrombocytopenia is rarely reported. We present a case of severe thrombocytopenia in a 70-year-old NSCLC patient caused by osimertinib combined with sitagliptin. After remission of thrombocytopenia, the patient was well tolerated with osimertinib re-administration in the absence of sitagliptin. We speculated that declined platelet count might be related to the interaction between osimertinib and sitagliptin by acting with a synergistic effect on platelets. Osimertinib rechallenge can be considered after discontinuing drugs that may contribute to platelet decline if possible, and making a careful assessment of complete blood count and risk of bleeding.
引用
收藏
页码:791 / 796
页数:6
相关论文
共 24 条
  • [1] Osimertinib in Patients With T790M Mutation-Positive, Advanced Non-Small Cell Lung Cancer: Long-Term Follow-Up From a Pooled Analysis of 2 Phase 2 Studies
    Ahn, Myung-Ju
    Tsai, Chun-Ming
    Shepherd, Frances A.
    Bazhenova, Lyudmila
    Sequist, Lecia, V
    Hida, Toyoaki
    Yang, James C. H.
    Ramalingam, Suresh S.
    Mitsudomi, Tetsuya
    Janne, Pasi A.
    Mann, Helen
    Cantarini, Mireille
    Goss, Glenwood
    [J]. CANCER, 2019, 125 (06) : 892 - 901
  • [2] Drug-associated thrombocytopenia
    Bakchoul, Tamam
    Marini, Irene
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2018, : 576 - 583
  • [3] Bertino E.M., 2020, CLIN CANCER RES, V27, P1604, DOI [10.1158/1078-0432.CCR-20-4084, DOI 10.1158/1078-0432.CCR-20-4084]
  • [4] Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
    Bray, Freddie
    Ferlay, Jacques
    Soerjomataram, Isabelle
    Siegel, Rebecca L.
    Torre, Lindsey A.
    Jemal, Ahmedin
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2018, 68 (06) : 394 - 424
  • [5] Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study
    Cao, Yabing
    Qiu, Xibin
    Xiao, Guangli
    Hu, Hao
    Lin, Tongyu
    [J]. PLOS ONE, 2019, 14 (08):
  • [6] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
    Cheng, Ying
    He, Yong
    Li, Wei
    Zhang, He-long
    Zhou, Qing
    Wang, Buhai
    Liu, Chunling
    Walding, Andrew
    Saggese, Matilde
    Huang, Xiangning
    Fan, Minhao
    Wang, Jia
    Ramalingam, Suresh S.
    [J]. TARGETED ONCOLOGY, 2021, 16 (02) : 165 - 176
  • [7] Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
    Goss, Glenwood
    Tsai, Chun-Ming
    Shepherd, Frances A.
    Bazhenova, Lyudmila
    Lee, Jong Seok
    Chang, Gee-Chen
    Crino, Lucio
    Satouchi, Miyako
    Chu, Quincy
    Hida, Toyoaki
    Han, Ji-Youn
    Juan, Oscar
    Dunphy, Frank
    Nishio, Makoto
    Kang, Jin-Hyoung
    Majem, Margarita
    Mann, Helen
    Cantarini, Mireille
    Ghiorghiu, Serban
    Mitsudomi, Tetsuya
    [J]. LANCET ONCOLOGY, 2016, 17 (12) : 1643 - 1652
  • [8] Sitagliptin: Anti-platelet effect in diabetes and healthy volunteers
    Gupta, Ashish Kumar
    Verma, Akhilesh Kumar
    Kailashiya, Jyotsna
    Singh, Surya Kumar
    Kumar, Narender
    [J]. PLATELETS, 2012, 23 (08) : 565 - 570
  • [9] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    [J]. EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [10] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
    Mok, T. S.
    Wu, Y. -L.
    Ahn, M. -J.
    Garassino, M. C.
    Kim, H. R.
    Ramalingam, S. S.
    Shepherd, F. A.
    He, Y.
    Akamatsu, H.
    Theelen, W. S. M. E.
    Lee, C. K.
    Sebastian, M.
    Templeton, A.
    Mann, H.
    Marotti, M.
    Ghiorghiu, S.
    Papadimitrakopoulou, V. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) : 629 - 640